The status and progress of neoadjuvant therapy for boardline resectable pancreatic cancer
10.3760/cma.j.cn113884-20200210-00059
- VernacularTitle:可能切除胰腺癌新辅助治疗的现状与进展
- Author:
Qingbo FENG
1
;
Xiaodong WANG
;
Tongtai LIU
;
Yuan GAO
;
Jie YAO
Author Information
1. 四川大学华西临床医学院，成都 610041
- From:
Chinese Journal of Hepatobiliary Surgery
2020;26(8):632-635
- CountryChina
- Language:Chinese
-
Abstract:
The proportion of boardline resectable pancreatic cancer (BRPC) is relatively high in patients with pancreatic cancer. At present, the main therapeutic treatment of BRPC is surgical resection after neoadjuvant therapy. Therefore, the neoadjuvant therapy of BRPC has drawn more and more attention in recent years. Once making a breakthroug in the treatment plan, it can greatly improve the overall prognosis of patients with pancreatic cancer. In this study, the development process, specific programs, advantages and disadvantages of each plan and the current research progress of BRPC neoadjuvant therapy are discussed.
